| Name | Parkview Care Center |
|---|---|
| Location | 811 N 1st Street, Osborne, Kansas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 58 |
| Occupancy Rate | 86.03% |
| Medicare ID (CCN) | 175409 |
| Legal Business Name | Osborne Development Co Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1366180424 |
| Organization Name | PARKVIEW HEALTH AND REHABILITATION CENTER LLC |
| Address | 811 N 1st St, Osborne, KS 67473 |
| Phone Number | 718-942-3483 |
News Archive
According to results published in today's issue of the journal Neuron, a study in mice proposes that dopamine and serotonin neurotransmitter systems in the brain occasionally get their signals crossed, causing delays in stabilizing mood.
Building on a shared vision to simplify diabetes management worldwide, Cellnovo, a London-based medical device company, and Home Diagnostics, Inc., a leader in diabetes products, today announced a strategic alliance that involves integrating technologies and developing distribution opportunities for Cellnovo's insulin patch pumps.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
The U.S. Food and Drug Administration today approved the Imugen Babesia microti Arrayed Fluorescent Immunoassay, for the detection of antibodies to Babesia microti (B. microti) in human plasma samples, and the Imugen Babesia microti Nucleic Acid Test (NAT), for the detection of B. microti DNA in human whole blood samples.
A new study establishes a molecular link that bridges two rare inherited disorders and explains why these diseases result in genetic instability. The research, published by Cell Press in the December 24th issue of the journal Molecular Cell, may lead to a better understanding of the complex mechanisms that enable cells to repair damaged DNA.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
According to results published in today's issue of the journal Neuron, a study in mice proposes that dopamine and serotonin neurotransmitter systems in the brain occasionally get their signals crossed, causing delays in stabilizing mood.
Building on a shared vision to simplify diabetes management worldwide, Cellnovo, a London-based medical device company, and Home Diagnostics, Inc., a leader in diabetes products, today announced a strategic alliance that involves integrating technologies and developing distribution opportunities for Cellnovo's insulin patch pumps.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
The U.S. Food and Drug Administration today approved the Imugen Babesia microti Arrayed Fluorescent Immunoassay, for the detection of antibodies to Babesia microti (B. microti) in human plasma samples, and the Imugen Babesia microti Nucleic Acid Test (NAT), for the detection of B. microti DNA in human whole blood samples.
A new study establishes a molecular link that bridges two rare inherited disorders and explains why these diseases result in genetic instability. The research, published by Cell Press in the December 24th issue of the journal Molecular Cell, may lead to a better understanding of the complex mechanisms that enable cells to repair damaged DNA.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $8125 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.67 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 1.17 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 29.52 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 6.3 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 5.85 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.92 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 1.09 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 8.15 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.2 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 23.73 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 59.68 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 17.58 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 29.35 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.06 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.58 | 95.98 |